Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

The effects of ex-vivo depletion of T lymphocytes from donor bone marrow using a monoclonal anti-T-cell antibody (CT-2) and complement on the outcome of allogeneic bone marrow transplantation was evaluated in a prospective, randomized, double-blind study of 40 patients with leukemia. Patients receiving T-cell-depleted bone marrow had a lower incidence of acute graft-versus-host disease than control patients (3 of 20 compared with 13 of 20; p = 0.004), and mortality due to acute graft-versus-host disease was reduced. Five patients in the T-cell-depletion group developed graft failure; all control patients had sustained engraftment (p less than 0.05). Clinically apparent relapse of leukemia occurred in 7 patients from the T-cell-depletion group and in 2 controls (p, not significant). Cytogenetic evidence of residual leukemia was also detected in the 5 patients with graft failure without overt relapse. Infections and overall survival were similar in the two groups. The effects of T-cell depletion on engraftment and recurrence of leukemia require further evaluation.

[1]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[2]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts , 1985 .

[3]  Kennedy,et al.  Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. , 1985, Blood.

[4]  Kennedy,et al.  Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. , 1985, Blood.

[5]  J. Finlay,et al.  Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. , 1985, Cancer treatment reports.

[6]  J. Finlay,et al.  Depletion of T cells from human bone marrow with monoclonal antibody CT-2 and complement. , 1984, Journal of biological response modifiers.

[7]  R. Gale,et al.  HOW DOES BONE-MARROW TRANSPLANTATION CURE LEUKAEMIA? , 1984, The Lancet.

[8]  J. Graham-Pole,et al.  Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. , 1984, Blood.

[9]  J. Kersey,et al.  Prevention and treatment of acute graft-versus-host disease. , 1984, Seminars in hematology.

[10]  R. Gale,et al.  Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. , 1984, The American journal of medicine.

[11]  D. Neville,et al.  EX-VIVO TREATMENT OF DONOR BONE MARROW WITH ANTI-T-CELL IMMUNOTOXINS FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE , 1984, The Lancet.

[12]  G. Janossy,et al.  DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTS , 1984, The Lancet.

[13]  K. Sullivan,et al.  Factors associated with graft rejection after HLA‐identical marrow transplantation for aplastic anaemia , 1983, British journal of haematology.

[14]  R. O'reilly.  Allogenic bone marrow transplantation: current status and future directions. , 1983, Blood.

[15]  D. Neville,et al.  Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Reagents selectively reactive with T cells and not murine stem cells. , 1983, Transplantation.

[16]  J. Sprent,et al.  Lethal GVHD Across Minor Histocompatibility Barriers: Nature of the Effector Cells and Role of the H‐2 Complex , 1983, Immunological reviews.

[17]  B. Dupont,et al.  Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.

[18]  A. Hess,et al.  Cyclosporin-A to prevent graft-versus-host disease: a pilot study in 22 patients receiving allogeneic marrow transplants. , 1983, Blood.

[19]  E. Reinherz,et al.  Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Kersey,et al.  PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION , 1982, The Lancet.

[21]  G. Janossy,et al.  USE OF ANTI-T-CELL MONOCLONAL ANTIBODY OKT3 TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA , 1982, The Lancet.

[22]  R. Gale.  Progress in bone marrow transplantation in man , 1982, Survey of immunologic research.

[23]  J. Kersey,et al.  Bone marrow transplantation across major histocompatibility barriers in mice. II. T cell requirement for engraftment in total lymphoid irradiation-conditioned recipients. , 1982, Transplantation.

[24]  J. Sprent,et al.  Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers , 1982, The Journal of experimental medicine.

[25]  L. Robison,et al.  A randomized study of the prevention of acute graft-versus-host disease. , 1982, The New England journal of medicine.

[26]  R. Good,et al.  TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLS , 1981, The Lancet.

[27]  J. Kersey,et al.  BONE MARROW TRANSPLANTATION ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS IN MICE EFFECT OF ELIMINATION OF T CELLS FROM DONOR GRAFTS BY TREATMENT WITH MONOCLONAL THY‐1.2 PLUS COMPLEMENT OR ANTIBODY ALONE , 1981, Transplantation.

[28]  R. Storb,et al.  Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. , 1981, Transplantation.

[29]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[30]  G. Janossy,et al.  REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIA , 1980, The Lancet.

[31]  J. Sloane,et al.  CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION , 1980, The Lancet.

[32]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[33]  R. Storb,et al.  ANTIHUMAN THYMOCYTE GLOBULIN FOR PROPHYLAXIS OF GRAFT‐VERSUS-HOST DISEASE: A RANDOMIZED TRIAL IN PATIENTS WITH LEUKEMIA TREATED WITH HLA‐IDENTICAL SIBLING MARROW GRAFTS , 1979, Transplantation.

[34]  J. Sprent,et al.  Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.

[35]  M. Ogawa,et al.  Circulating Erythropoietic Precursors Assessed in Culture: Characterization in Normal Men and Patients With Hemoglobinopathies , 1977 .

[36]  S. Feig,et al.  Gene Markers in Human Bone Marrow Transplantation 1 , 1977, Vox sanguinis.

[37]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[38]  M. Tyan.  MODIFICATION OF SEVERE GRAFT‐VERSUS‐HOST DISEASE WITH ANTISERA TO THE &thetas; ANTIGEN OR TO WHOLE SERUM , 1973, Transplantation.

[39]  B. Pike,et al.  Human bone marrow colony growth in agar‐gel , 1970, Journal of cellular physiology.

[40]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[41]  D. V. van Bekkum,et al.  THE SELECTIVE ELIMINATION OF IMMUNOLOGICALLY COMPETENT CELLS FROM BONE MARROW AND LYMPHATIC CELL MIXTURES , 1964, Transplantation.

[42]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[43]  S. Feig,et al.  High-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results. , 1985, Seminars in oncology.

[44]  R. Gale,et al.  Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants. , 1984, Cancer treatment reports.

[45]  N. Rose,et al.  Manual of clinical immunology , 1976 .

[46]  A. Böyum.  A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.